Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C16H13ClN2O.ClH |
| Molecular Weight | 321.201 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.OC1(N2CCN=C2C3=CC=CC=C13)C4=CC=C(Cl)C=C4
InChI
InChIKey=NIUFFPYONFMTAH-UHFFFAOYSA-N
InChI=1S/C16H13ClN2O.ClH/c17-12-7-5-11(6-8-12)16(20)14-4-2-1-3-13(14)15-18-9-10-19(15)16;/h1-8,20H,9-10H2;1H
Mazindol is an amphetamine-like medicine which was developed by Sandoz in 1967 and approved by FDA for the treatment of obesity and Duchenne muscular dystrophy under the names Sanorex and Mazanor. The exact mechanism of action is unknown, but possibly involves the stimulation of beta-adrenergic receptors and inhibition of monoamine reuptake. Both Sanorex and Mazanor were withdrawn from the market by reason other than safety. NLS Pharma now is developing mazindol for Attention Hyperactivity Disorder in adults (phase II).
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
4.09 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27066959/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
MAZINDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
35.63 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27066959/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
MAZINDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
7.66 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27066959/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
MAZINDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine. | 1999 Jul |
|
| Decreased densities of dopamine and serotonin transporters and of vesicular monoamine transporter 2 in severely kainic acid lesioned subregions of the striatum. | 2001 |
|
| Anticocaine catalytic antibodies have no affinity for RTI compounds: implications for treatment. | 2001 Aug |
|
| Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. | 2001 Aug 13-27 |
|
| Biochemical and immunohistological changes in the brain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse. | 2001 Jan |
|
| [Hyperlipidemia with obesity]. | 2001 Mar |
|
| Interactions of tryptamine derivatives with serotonin transporter species variants implicate transmembrane domain I in substrate recognition. | 2001 Mar |
|
| [Monoaminergic anorectic agents]. | 2001 Nov |
|
| Effects of dopaminergic and cholinergic interactions on rat behavior. | 2001 Oct 5 |
|
| The potential of dopamine agonists in drug addiction. | 2002 Apr |
|
| Periwound dopaminergic sprouting is dependent on numbers of wound macrophages. | 2002 Mar |
|
| Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. | 2002 Mar 29 |
|
| Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter. | 2002 Sep 12 |
|
| Changes in GABA(B) receptor mRNA expression in the rodent basal ganglia and thalamus following lesion of the nigrostriatal pathway. | 2003 |
|
| 1-Methyl-4-phenylpyridinium accumulates in cerebellar granule neurons via organic cation transporter 3. | 2003 Apr |
|
| Binding site of salsolinol: its properties in different regions of the brain and the pituitary gland of the rat. | 2003 Jan |
|
| Discriminative stimulus effects of (-)-ephedrine in rats: analysis with catecholamine transporter and receptor ligands. | 2003 Jun 5 |
|
| Dopamine transporter as target for drug development of cocaine dependence medications. | 2003 Oct 31 |
|
| Differential effects of prolonged high frequency stimulation and of excitotoxic lesion of the subthalamic nucleus on dopamine denervation-induced cellular defects in the rat striatum and globus pallidus. | 2004 Dec |
|
| Neurochemical effects of chronic dietary and repeated high-level acute exposure to chlorpyrifos in rats. | 2005 Nov |
|
| Enhanced dopamine uptake in the striatum following repeated restraint stress. | 2005 Sep 1 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: DOI: 10.1604/9780440235378, Catalano J., 'The Women's Pharmacy: An Essential Guide to What Women Should Know About Prescription Drugs' (2008), p.218, Retrieved from https://books.google.es/books?id=WueSNTyQq6sC&dq
The usual dose is 1 mg three times a day an hour before meals or 2 mg once a day an our before lunch.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
TYC95TXB8Q
Created by
admin on Sat Dec 16 10:14:38 GMT 2023 , Edited by admin on Sat Dec 16 10:14:38 GMT 2023
|
PRIMARY | |||
|
DTXSID60974091
Created by
admin on Sat Dec 16 10:14:38 GMT 2023 , Edited by admin on Sat Dec 16 10:14:38 GMT 2023
|
PRIMARY | |||
|
26859-70-1
Created by
admin on Sat Dec 16 10:14:38 GMT 2023 , Edited by admin on Sat Dec 16 10:14:38 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
3041799
Created by
admin on Sat Dec 16 10:14:38 GMT 2023 , Edited by admin on Sat Dec 16 10:14:38 GMT 2023
|
PRIMARY | |||
|
DBSALT002359
Created by
admin on Sat Dec 16 10:14:38 GMT 2023 , Edited by admin on Sat Dec 16 10:14:38 GMT 2023
|
PRIMARY | |||
|
58535-70-9
Created by
admin on Sat Dec 16 10:14:38 GMT 2023 , Edited by admin on Sat Dec 16 10:14:38 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
